SOURCE-LINKED STUDY SUMMARY
Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics.
What was studied?
Abstract-based design report for SURPASS-CVOT, a randomized, double-blind trial comparing weekly subcutaneous tirzepatide up to 15 mg with dulaglutide 1.5 mg.
What changed?
No comparative cardiovascular results were available. The event-driven primary outcome was time to cardiovascular death, myocardial infarction or stroke, continuing until at least 1,615 events.
Who was studied?
The trial randomized 13,299 adults across 640 sites in 30 countries; mean age was 64.1 years, with longstanding type 2 diabetes and established cardiovascular disease.
Studied exposure
Not extracted or not reported in this source.
What remains uncertain?
This publication reports design and baseline characteristics while the trial was ongoing; it cannot establish tirzepatide’s cardiovascular safety or superiority.
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1016/j.ahj.2023.09.007